Trial · NCT00455975

High-dose Bevacizumab in Advanced Renal Carcinoma Patients

NCT00455975, Phase 2, Completed, SCRI Development Innovations, LLC; results first posted 2014-12-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. High-dose Bevacizumab in Advanced Renal Carcinoma Patients. Trials, record NCT00455975. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00455975

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: High-dose Bevacizumab in Advanced Renal Carcinoma Patients
NCT number: NCT00455975
Status: Completed
Phases: Phase 2
Enrollment: 119 participants, actual
Lead sponsor: SCRI Development Innovations, LLC
Conditions: Renal Cancer, Kidney Cancer
Interventions: Bevacizumab
First posted: 2007-04-04
Last updated: 2014-12-22
Results first posted: 2014-12-22

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression-free Survival	18 months (expected)	Progression-free survival is measured from Day 1 of study drug administration to disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death on study. Progression is defined in RECIST v1.1 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Secondary	Overall Survival (OS)	18 months	Measured from date of study entry to date of death due to any cause.
Secondary	Objective Response Rate	18 months	The number of patients with observed complete response \[CR\] or partial response \[PR\]. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR
Secondary	Overall Tolerability and Toxicity of High-dose Bevacizumab	18 months	Number of patients treated with high-dose bevacizumab experiencing Grade 3/4, treatment-related toxicities

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression-free Survival	18 months (expected)		months	MEDIAN
SECONDARY	Overall Survival (OS)	18 months		months	MEDIAN
SECONDARY	Objective Response Rate	18 months		participants	NUMBER
SECONDARY	Overall Tolerability and Toxicity of High-dose Bevacizumab	18 months	All patients treated with Bevacizumab therapy were assessed for Grade 3/4 toxicities	participants	NUMBER

Source ClinicalTrials.gov

Results by group48

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Progression-free Survival	Weekly Avastin		6.0	95% Confidence Interval 3.5 to 9.1	months
Progression-free Survival	Bi-weekly Avastin		5.7	95% Confidence Interval 3.6 to 9.2	months
Overall Survival (OS)	Weekly Avastin		26.9	95% Confidence Interval 12.9 to NA	months
Overall Survival (OS)	Bi-weekly Avastin		18.4	95% Confidence Interval 12.0 to 28.9	months
Objective Response Rate	Weekly Avastin		9		participants
Objective Response Rate	Bi-weekly Avastin		6		participants
Overall Tolerability and Toxicity of High-dose Bevacizumab	Weekly Avastin	Anemia	2		participants
Overall Tolerability and Toxicity of High-dose Bevacizumab	Bi-weekly Avastin	Anemia	5		participants
Overall Tolerability and Toxicity of High-dose Bevacizumab	Weekly Avastin	Thrombocytopenia	1		participants
Overall Tolerability and Toxicity of High-dose Bevacizumab	Bi-weekly Avastin	Thrombocytopenia	0		participants

1 to 10 of 48Source ClinicalTrials.gov

See all 48 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Weekly Avastin	58
Overall Study	STARTED	Bi-weekly Avastin	61
Overall Study	COMPLETED	Weekly Avastin	40
Overall Study	COMPLETED	Bi-weekly Avastin	40
Overall Study	NOT COMPLETED	Weekly Avastin	18
Overall Study	NOT COMPLETED	Bi-weekly Avastin	21

Source ClinicalTrials.gov

Adverse events180

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	FATIGUE	General disorders	Weekly Avastin	37	58
other	FATIGUE	General disorders	Bi-weekly Avastin	50	61
other	PROTEINURIA	Renal and urinary disorders	Weekly Avastin	34	58
other	PROTEINURIA	Renal and urinary disorders	Bi-weekly Avastin	39	61
other	NAUSEA	Gastrointestinal disorders	Weekly Avastin	21	58
other	NAUSEA	Gastrointestinal disorders	Bi-weekly Avastin	22	61
other	Anorexia	Metabolism and nutrition disorders	Weekly Avastin	14	58
other	Anorexia	Metabolism and nutrition disorders	Bi-weekly Avastin	24	61
other	HEADACHE	Nervous system disorders	Weekly Avastin	18	58
other	HEADACHE	Nervous system disorders	Bi-weekly Avastin	17	61

1 to 10 of 180Source ClinicalTrials.gov

See all 180 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Weekly Avastin
Total, all-cause mortality	Bi-weekly Avastin
Total, other adverse events	Weekly Avastin	58	58
Total, other adverse events	Bi-weekly Avastin	61	61
Total, serious adverse events	Weekly Avastin	33	58
Total, serious adverse events	Bi-weekly Avastin	35	61

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Weekly Avastin vs Bi-weekly Avastin: Objective Response Rate	Trial comparisons
Weekly Avastin vs Bi-weekly Avastin: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00455975

GET https://conductscience.org/api/trials/v1/NCT00455975/results?page=2

API reference For AI assistants